|
CRISPR/Cas9 screens
|
|
1
|
57
|
1 October 2024
|
|
How to Interpret and Utilize the Evidence Scores in Open Targets?
|
|
1
|
99
|
27 September 2024
|
|
Drug target affinity
|
|
1
|
72
|
13 September 2024
|
|
How to group associations by therapeutic area?
|
|
12
|
553
|
12 September 2024
|
|
Older versions of OpenTargets data
|
|
4
|
122
|
10 September 2024
|
|
Estimated prevalence or incidence to diseases
|
|
4
|
195
|
14 August 2024
|
|
Correlation between disease and tissue
|
|
2
|
73
|
14 August 2024
|
|
Treatment of drug combinations
|
|
2
|
69
|
29 July 2024
|
|
Seeking Advice on Colocalization of GWAS Signals with OpenTargets Summary Statistics
|
|
0
|
39
|
24 July 2024
|
|
Tractability - Half-life Data
|
|
1
|
58
|
18 July 2024
|
|
CRISPRbrain Data Interpretation
|
|
4
|
85
|
16 July 2024
|
|
TWAS hub Integration Initiative
|
|
1
|
30
|
16 July 2024
|
|
Update of AstraZeneca PheWAS Portal
|
|
2
|
264
|
10 June 2024
|
|
Data Sharing Roadmap/Timeline for Open-IBD Project
|
|
2
|
98
|
3 June 2024
|
|
BigQuery Release Date
|
|
3
|
208
|
30 May 2024
|
|
"ratio TG/HDL custom" is missing?
|
|
2
|
126
|
23 May 2024
|
|
Inheritance model (Dominant, Recessive etc) in ClinVar and Genomics England
|
|
0
|
68
|
20 May 2024
|
|
Data source scores ot_genetics_portal vs L2G in final association score
|
|
1
|
114
|
8 May 2024
|
|
APOL1 variants with established role in kidney diseases
|
|
0
|
104
|
23 April 2024
|
|
Question regarding the release date for Open Targets Genetics Version 9
|
|
3
|
387
|
19 April 2024
|
|
RSCRIPT - How to have the nearest gene for a thousand of rsid
|
|
1
|
169
|
16 April 2024
|
|
ClinVar and GEL with LoF annotation
|
|
1
|
87
|
22 March 2024
|
|
Loss-of-function * risk between EDDM3A and Alzheimer disease
|
|
2
|
108
|
21 March 2024
|
|
FH Alzheimer disease dementia custom
|
|
0
|
95
|
21 March 2024
|
|
Star alleles from PharmGKB
|
|
3
|
265
|
20 March 2024
|
|
Merge of associated targets and associated targets beta functionality?
|
|
1
|
131
|
16 February 2024
|
|
FEV/FEC ratio looks weired
|
|
2
|
171
|
14 February 2024
|
|
Expanding Target Tractability Assessment to Include Alternative Modalities
|
|
1
|
127
|
7 February 2024
|
|
Why are some drug target proteins not classed as having approved drugs on OT
|
|
4
|
220
|
5 February 2024
|
|
Missed models in Gene burden test
|
|
1
|
151
|
20 January 2024
|